Search PubMed⌕ Search

Biomedical subjects

N Giladi

Publications and source records attributed to N Giladi.

82 records · Page 5Linked to original sources
PubMed1990

Hemiparkinsonism-hemiatrophy syndrome: clinical and neuroradiologic features.

We evaluated 11 patients with hemiparkinson-hemiatrophy syndrome, 6 with body and contralateral cerebral hemispheric hemiatrophy, 4 with only body hemiatrophy, and 1 with just brain hemiatrophy. The mean age of symptom onset was 38.1 years (range, 18 to 54) with 5.2 +/- 3.1 (mean +/- SD) years of illness until the last follow-up visit. The presenting symptom was unilateral tremor in 6 patients, hand dystonia in 2, bradykinesia in 2, and abnormal gait in 1 patient. Three patients had a good response to levodopa, 4 had moderate response, and 2 patients had a poor response. During a mean follow-up period of 1.7 years (range, 4 months to 5 years), the Hoehn and Yahr score changed in only 3 patients: 2 gained 1.5 points and 1 gained 3 points over 2.5 years. We discuss the association between hemiparkinsonism-body hemiatrophy and contralateral hemispheric hemiatrophy, and raise the possibility of early childhood brain insult with delayed-onset parkinsonism.

Adolescent↗
PubMed1984

Pharyngoconjunctival fever.

Sixteen infants and toddlers from four kibbutz day nurseries contracted an illness comprising fever, conjunctivitis, respiratory infection, lymphadenopathy, otitis media, and a new sign, migratory palpebral erythema. Adenovirus type 3 was isolated from the pharynx of the first three children taken ill.

Adenoviridae Infections↗
PubMedDate not supplied

The effect of deprenyl treatment on directional and velocity control of arm movement in patients with early stages of Parkinson's disease.

Visual motor control (VMC) of arm movements is disturbed in patients with Parkinson's disease. The effect of antiparkinsonian medications on VMC is unknown. To assess the effect of deprenyl, a monoamine oxidase type B inhibitor, on VMC in the early stages of parkinsonism. Fourteen recently diagnosed, unmedicated patients with primary degenerative parkinsonism, mean age 61.9 +/- 2.8 years, were assessed by a computerized VMC system for tracking and tracing on a sine wave, circle, and square. Score was given for total time of test performance, directional error, arm velocity, and number of interruptions in tracking. All patients performed the first VMC test at baseline, prior to any antiparkinsonian treatment. The second test was performed after a month of treatment with 2.5 mg/d of deprenyl, and the third test was done after an additional month of treatment with 10 mg/d of deprenyl. Results were compared with 15 healthy volunteers with a mean age of 63.1 +/- 1.2 years. Parkinsonian patients performed significantly poorer on the VMC when compared to controls. Tracing was more affected than tracking. Tracing total time was almost twice as long as for controls (p < .0005). Treatment with 2.5 mg/d and 10 mg/d of deprenyl improved performance significantly (p < .05 and p < .005, respectively). Velocity of arm movement was not affected by deprenyl treatment in either dose. Directional control (tracing), severely disturbed in the parkinsonian group, improved back to the performance of healthy controls after 10 mg/d of deprenyl. In recently diagnosed parkinsonian patients internally guided VMC tasks were disturbed more than externally guided ones. Deprenyl treatment selectively improved directional control of arm movement in a dose related manner.

Female↗
PubMedDate not supplied

Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.

Rasagiline mesylate (TVP-1012) is a potent, selective, non-reversible MAO-B inhibitor, without the tyramine-potentiating effect and with neuroprotective activities. The benefit of rasagiline as monotherapy in patients with early Parkinson's disease (PD) has already been reported. To evaluate the safety, tolerability, and clinical effect of rasagiline as adjunctive therapy to levodopa, a multicenter, double-blind, randomized, placebo-controlled, parallel-group study (0.5, 1, and 2 mg/d) was conducted for 12 weeks in 70 patients with PD (mean age, 57.4 y; mean disease duration, 5.7 y; 32 patients had motor fluctuations). A beneficial clinical effect was observed in fluctuating patients treated with rasagiline (all doses), expressed as a decrease in total Unified Parkinson's Disease Rating Scale (UPDRS) score (23.0% vs 8.5% in the placebo group). The treatment effect was still evident 6 weeks after drug discontinuation (in all doses). The safety and tolerability of rasagiline were good. Adverse events were no different than those of patients taking placebo. Almost complete platelet MAO-B inhibition was obtained at all rasagiline doses. This study has demonstrated that rasagiline (up to 2 mg/day) has a good safety profile and a beneficial clinical effect in fluctuating patients with PD when given as an add-on to chronic levodopa therapy.

Adult↗
PubMedDate not supplied

Tetrabenazine treatment in movement disorders.

Tetrabenazine (TBZ) is a catecholamine depletor used for the treatment of a variety of movement disorders. The purpose of this study was to assess the efficacy of TBZ in a retrospective chart review in 3 tertiary care movement disorders centers over long-term treatment. Of 150 patients to whom TBZ was prescribed, 118 were followed up and assessed using the Clinical Global Impression of Change (CGIC), (-3 to +3), a composite grade from a patient and caregiver scale over variable periods. The patients had a variety of hyperkinetic movement disorders including dystonia (generalized and focal: axial, Meige syndrome, torticollis, blepharospasm, bruxism), Huntington disease (HD) or other choreas, tardive dyskinesia (TD) or akathisia, and Tourette syndrome. Mean patient age was 48.8 +/- 18.7 years; 48 were men (40.7%) with a mean disease duration of 93 months. The mean follow-up time was 22 months and the mean TBZ dose was 76.2 +/- 22.5 mg/d (median 75 mg, range 25-175 mg/d). The mean CGIC score was +1 (mild improvement). The group of patients who scored +3 on the CGIC (very good improvement) represented 18.6% (n = 22) of all patients. They had HD or other types of chorea 7.6% (n = 9), facial dystonia/dyskinesia (n = 7, 5.9%), 1 with TD, 2 with trunk dystonia, 2 with Tourette syndrome, and 1 with tardive akathisia. This group had the longest treatment duration and received a mean TBZ dose of 70.5 mg/d (median 75 mg/d) for a mean of 25.4 +/- 21.3 months. The report concludes that TBZ is a moderately effective treatment of a large variety of hyperkinetic movement disorders, with excellent effects in a subgroup with chorea and facial dystonia/dyskinesias.

Adult↗
PubMedDate not supplied

Cross-sectional study of the prevalence of Parkinson's disease in the Kibbutz movement in Israel.

BACKGROUND: The prevalence of PD in Israel has never been studied. OBJECTIVE: To study the prevalence of Parkinson's disease (PD) in a well-defined population of the Kibbutz Movement in Israel. The population which lives in kibbutzim is unique because all these people are under close medical care and the demographic data regarding this population are well defined. METHODS: Questionnaires were sent to the medical clinics of 270 kibbutzim in Israel to provide demographic details as well as medical information about all PD patients who have been diagnosed by neurologists. Two subgroups were determined: aged over 40 years and over 60 years. RESULTS: Of the total of 73,767 people studied, PD was diagnosed in 180 patients yielding a cross-sectional prevalence rate of 0.24% for the entire population. Age-adjusted prevalence was 0.94% in the population over 60 years and 0.33% in the population over 40 years. The mean age of disease onset was 66.7 +/- 11 years. Topographic location was not found to be a risk factor for the development of PD in Israel. CONCLUSIONS: The prevalence of PD in the Israeli kibbutz population is similar to that reported in most other population-based studies. We observed an older age at symptom onset in the Kibbutz Movement than most other epidemiological studies.

Adult↗